1Research Scholar,
2Associate Prof.,
*Corresponding Author E-mail:mahadevammalingaiah11@gmail.com
HIV is a retrovirus that selectively targets CD4+ T cells and HIV infection is prevalent on a global scale. The treatment involves HAART therapy. The appropriate use of HAART significantly reduces HIV replication. TLD is one such HAART regimen that contains Dolutegravir (DTG) as a preferred first -line treatment for HIV, comprising two NRTIs (TDF 300 mg, 3TC 300 mg) and one INSTI (DTG 50 mg) in a fixed- dose combination. This regimen effectively suppresses plasma HIV RNA load to undetectable levels, restores CD4+ cell counts, and offers improved tolerability and drug-resistance barriers compared to older Integrase inhibitors & NRTIs.
The present Ambispective study compared the efficacy of the TLD regimen in 1021 patients ageing (19-75 years) living with HIV-1. Data was collected prospectively through follow-up visits and retrospectively through medical records.
Objectives were comparing immunologic response (CD4 cell count change), virologic response (viral load reduction), in association with Medication adherence,
Of the 1021 PLWH, 51.3% were males, 46.5% were females while 2.2% were transgender. The study demonstrated good CD4 count elevation at 6, 12 and 24 months of TLD regimen initiation while the viral load had marked suppression to <1000 c/ml after 36 to 48 months of treatment.
Study makes a significant increase in CD4+ T cell count with an achievement of undetectable viral load levels over time. This highlights the regimen's potential for HIV infection management with significant contribution to the optimization of HIV treatment outcomes, enhancing patient quality of life, and advancing progress towards achieving the desired goals for HIV control.
Efficacy, Safety, PLWH, CD4 count, Plasma viral load
